Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

4 Customer Reviews

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M4ewZ2N6fG:2b4jpZ:Kh[XO|YYm= M1G5ZlQ5KGh? M13jeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u MmHxNlE{QDhzOUG=
human colon cancer cell line (LoVo cells) NG\MOGlRem:uaX\ldoF1cW:wIHHzd4F6 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGOxbH;uJINidmOncjDj[YxtKGyrbnWgLGxwXm9iY3XscJMqKHW|aX7nJG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2u MlroNVE2QTF3MEW=
human LoVo cells MlPsVJJwdGmoZYLheIlwdiCjc4PhfS=> NEnicWo1QCC2bzC3NkBp M{e3TGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NEjiOI8zOjF6MkmyPS=>
P19 cells M{[2PGZ2dmO2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDy[YNmeHSxcjDpckBROTliY3XscJMtKEmFNUC9NE4xODJizszNMi=> M3PYb|E2PzdzNEG5
human BJ cells M{\2fWN6fG:2b4jpZ:Kh[XO|YYm= NIjUeVg4OiCq NFjHc5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkCwNkDPxE1w M1HMNVIzQTJzMEix
human HT-29 cells MXjGeY5kfGmxbjDhd5NigQ>? NWjY[WdtOiCq MVXF[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= NH64NGszOTR{OEO3OS=>
human A549 cells Ml\BR5l1d3SxeHnjxsBie3OjeR?= MlGzO|IhcA>? NVXJZZJWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= M3i2NlE5PDh2N{e1
human HT-29 cells MUHGeY5kfGmxbjDhd5NigQ>? NFOzWWxKdmirYnn0bY9vKG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheG:2ZX70bYFtKGmwIHj1cYFvKEiWLUK5JINmdGy|IIXzbY5oKEqFMTDkfYUhe3SjaX7pcoch[nliZnz1c5Jme2OnbnPlJJBt[XSnIILlZYRmeiCjc4PhfUwhUUN3ME2yMlUhdk1? Ml;jNlE2OTN{OUO=
human HT-29 cells NFnTV4hHfW6ldHnvckBie3OjeR?= MWCyJIg> NF2zfGJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> NXnHdXRtOjF7N{OxNFE>
Sf9 cells MYDGeY5kfGmxbjDhd5NigQ>? NVXafI5pUW6qaXLpeIlwdiCxZjDoeY1idiCVeXug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0{KG6PLh?= Mn;uNVg5OjN5OES=
human HUVEC MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 MVi0PEB1dyB5MjDo M1;ZNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= MX2yNlE5Ojl{OR?=
P19 cells MWrGeY5kfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy|LDDJR|UxRTRibl2u NULHeIxGOTV5N{G0NVk>
Sf9 cells M3zl[2Z2dmO2aX;uJIF{e2G7 NGfpNZlKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFEhdWmwIHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUB?= NE\hU5EyPzNzNUi1Ny=>
Sf21 cells MlT4SpVv[3Srb36gZZN{[Xl? M4HJW2lvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> NESze|gyPzB6OEC1PS=>
human colon carcinoma cell line HCT116 M2nFT2Z2dmO2aX;uJIF{e2G7 NGLZdo1Ed26lZX70doF1cW:wIILldZVqemWmIH\vdkBoem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCuaX7lJGhEXDFzNjygTWM2OD14IH7NMi=> NHnoUI4yPTV|N{O0OS=>
human ST486 cells MXrQdo9tcW[ncnH0bY9vKGG|c3H5 MXm0PEB1dyB5MjDo NHW3XodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPUOFg3KGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PyCwTT6= M4jlNFIzOTh{OUK5
human MDA-MB-231 cells NHXwUHZEgXSxdH;4bYPDqGG|c3H5 MnLQO|IhcA>? MlvLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= NHq0SW0yQDR6NEe3OS=>
P19 cells MWTGeY5kfGmxbjDhd5NigQ>? NFHxS5dKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v NVfn[mo4OTV5N{G0NVk>
human DLD1 cells NHHwS25Rem:uaX\ldoF1cW:wIHHzd4F6 NEfZTpM1QC15MjDo MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? Ml7ZNlIyQDJ7Mkm=
insect cells NX70[pF6TnWwY4Tpc44h[XO|YYm= M{npXWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v M3;Hc|E6OTd7MEe2
V79 MZ cells MkDQSpVv[3Srb36gZZN{[Xl? MmrqTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> M{Tze|I1PDJ{NUG5
P19 cells M{\sVWZ2dmO2aX;uJIF{e2G7 NYjm[IhzUW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IHnuJHAyQSClZXzsd{whUUN3ME2xOEBvVS5? M3m5[FE2PzdzNEG5
Sf9 cells MX\GeY5kfGmxbjDhd5NigQ>? M3SxeVIxKG2rboO= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> M1HT[lE4OzF3OEWz
human PBMC MXPGeY5kfGmxbjDhd5NigQ>? NYXyXHNwOjRiaB?= M4\KdHN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= M1LaRlE5PTh3MES2
human A549 cells MYfDfZRwfG:6aXRCpIF{e2G7 NV3HVm9QPDhiaB?= MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUKwJI5ONg>? NILDZoszPTh{NUmzOC=>
human CEM cells NH[wPGNEgXSxdH;4bYPDqGG|c3H5 MornO|IhcA>? NGTZVG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v M1rPV|IzQTJzMEix
human HeLa cells NWTXcGVSS3m2b4TvfIlkyqCjc4PhfS=> NEC3cIw1QCCq MmftR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JI5ONg>? MmrlNlU5OjV7M{S=
human PC3 cells M1rpOGN6fG:2b4jpZ:Kh[XO|YYm= NFrTb3c1QCCq NFTOZ|ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w MnTZNlU5OjV7M{S=
human SF268 cells M4jZTmN6fG:2b4jpZ:Kh[XO|YYm= MYi0PEBp Mk\4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5? M{LNSVIyPTF|Mkm0
human MCF7 cells NUfyO5dUS3m2b4TvfIlkyqCjc4PhfS=> MoPKOFghcA>? M{jWVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? NEHQcGszOTN6OEG5NS=>
HEK293 cells NFLjPZVEgXSxdH;4bYPDqGG|c3H5 NYXP[JpRPzJiaB?= MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmekeubzDhd5NigSxiSVO1NF02PiCwTT6= Mm\vNlQ4PjN{NkK=
HUE cells MXrGeY5kfGmxbjDhd5NigQ>? MXq5NEBucW6| MkjGTY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iSGXFJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hfHKnYYTl[EBnd3JiOUCgcYlveyCkZX\vdoUhXkWJRjDjbIFtdGWwZ3WgZpkhTUyLU1GsJGlEPTB;N{Cgcm0v NFGzSIgzODF5MEG2Ny=>
human A431 cells M{PLb2N6fG:2b4jpZ:Kh[XO|YYm= NVLxV5VLOjRiIHi= M1LLW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= MXWyNlU1OTB3MR?=
human Jurkat cells NXf3dJpSWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnfjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDKRWs{KGW6cILld5NqdmdiSVyyMZN1cW23bHH0[YQhcHWvYX6gTpVzc2G2IHPlcIx{NCCLQ{WwQVcyKG6PLh?= M{TtXlE6PDJ5MkCz
HEK293 cells NH;lNnVHfW6ldHnvckBie3OjeR?= M1TWXWlvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? NU\F[VhDOTV5N{G0NVk>
human KE-97 cells NV;VdWdUS3m2b4TvfIlkyqCjc4PhfS=> MlPUO|IhcA>? MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= MnjONlQ{Ojh{OEO=
human CHOK1 cells NIPMNVZEgXSxdH;4bYPDqGG|c3H5 NWe1WZVqPDhiaB?= M3m4SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNJV0tzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjF|IN88UU4> MnvsNlE2OTN{OUS=
mouse NIH/3T3 cells NF71[3pEgXSxdH;4bYPDqGG|c3H5 M4\FVVk3KGh? MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MoLNNlQ{PjF3MkG=
human A2780 cells MV\DfZRwfG:6aXRCpIF{e2G7 NYO4fmtXQTZiaB?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w NGXz[pgzPDN4MUWyNS=>
human 8505C cells MYnDfZRwfG:6aXRCpIF{e2G7 MV[5OkBp NIf6c3VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NHXsWYIzPDN4MUWyNS=>
human 518A2 cells Mki3R5l1d3SxeHnjxsBie3OjeR?= NHLLWIw6PiCq MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC1NVhCOiClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H589yNKEmFNUC9NE4zKM7:TT6= M3vmb|I1OzZzNUKx
human HuH7 cells MnPaR5l1d3SxeHnjxsBie3OjeR?= MmG2O|IhcA>? MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= M4PSNVI1OzJ6Mkiz
FL5.12-Akt1 cells MlL1VJJwdGmoZYLheIlwdiCjc4PhfS=> NXvoU|NTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHVDVwMUKtRYt1OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5{OTFOwG0v M1LvSVE3PDB|NkK2
human MiaPaCa-2 cells NVrQc|RQWHKxbHnm[ZJifGmxbjDhd5NigQ>? NF6wPVNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3pZXBiS2FvMjDj[YxteyxiSVO1NF0xNjN5IN88UU4> Mn[2NVY1OTN5OEC=
human BGC823 cells M1\INmN6fG:2b4jpZ:Kh[XO|YYm= Ml\tO|IhcA>? NGjYdm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|ODFOwG0v NYDuOlhHOjR|MkiyPFM>
human MCF7 cells NF;GUoNEgXSxdH;4bYPDqGG|c3H5 NWrtTWw6QTZiaB?= NGG5bVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TT6= MYGyOFM3OTV{MR?=
human A549 cells MlzwR5l1d3SxeHnjxsBie3OjeR?= NHzac5k6PiCq MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD62JO69VS5? NYLYPGplOjR|NkG1NlE>
HEK293 cells NH7TWYVEgXSxdH;4bYPDqGG|c3H5 NXfUeZo3S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? M{nHTVI2OzF4M{G3
human Raji cells  NYTiUJZES3m2b4TvfIlkyqCjc4PhfS=> NI\Tb5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= NF\2UpgzPTNzNkOxOy=>
human HepG2 cells M3TpOmN6fG:2b4jpZ:Kh[XO|YYm= M13QRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh|ryPLh?= MkXtNlU{OTZ|MUe=
human BJ cells M{SxfWN6fG:2b4jpZ:Kh[XO|YYm= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> Mn3qNlU{OTZ|MUe=
human U937 cells M{nPbGN6fG:2b4jpZ:Kh[XO|YYm= NHzCS5NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{NCCLQ{WwQVIh|ryPLh?= NF;Rc3YyPzB6OEC2Oy=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Akt / Akt / PARP /Cleaved PARP; 

PubMed: 24174874     


Western blot analysis for Akt, P-Akt, and cleaved poly(ADP-ribose) polymerase. U87 cells were incubated with 200 nM, 10 nM, and 0.1 nM of staurosporine encapsulated in liposomes and staurosporine for 32 hours.

FAK / RIP; 

PubMed: 15121855     


Western blot (WB) analysis of BT-20 and BT-474 lysates treated with staurosporine (200 nM). Control cells were treated with dimethyl sulfoxide for 18 h.

Ambra1; 

PubMed: 24587252     


SW620 cells treated with various doses of staurosporine for 6 h. Ambra1 levels were measured by Western blot. 

24174874 15121855 24587252
Growth inhibition assay
Cell viability; 

PubMed: 25215174     


Staurosporine reduces cerebellar astrocytes viability. (a) Cerebellar astrocytes were treated with staurosporine 0.1 μM, 0.25 μM, and 0.5 μM for 24 h and the cell viability was measured by MTT transformation. (b) Cerebellar astrocytes were treated with staurosporine 0.5 μM for 6, 12, and 24 h and the cell viability was measured by MTT transformation. Data are presented as mean ± SEM of four independent experiments. ∗ is significantly different from control (P < 0.05).

25215174
Immunofluorescence
Tubulin / Actin; 

PubMed: 25215174     


Morphological changes of astrocytes induced by St are evidenced by the rearrangement of cytoskeletal proteins. Astrocytes were treated with St (0.5 μM) for 12 hours and then were labelled with rhodamine-phalloidin or immunostained for tubulin. Representative images of phase contrast, rhodamine-phalloidin, and tubulin are shown in control and St treated astrocytes. Scale bar represents 50 μm.

Phalloidin / Type II collagen; 

PubMed: 22684244     


Cell were cultured in the absence (a-f) or presence of staurosporine (STSN, 5 × 10-9M) or cytochalasin D (CD, 1 µg/ml) for 1 (upper panel) or 2 (lower panel) days at low density and stained for F-actin (Phalloidin) and type II collagen (Type II). STSN: Staurosporine.

Pyk2; 

PubMed: 19880522     


Pyk2 translocates to the nucleus upon staurosporine addition to ID8 cells. Confocal immunofluorescent analysis of endogenous Pyk2 upon DMSO (control) or 1 μm staurosporine addition for 2 h. The scale bar is 10 μm. 

Annexin; 

PubMed: 15140398     


Induction of apoptosis with staurosporine resulting in activation of the ICE-NIRF probe. Gli36 cells were treated with 50 µM staurosporine for 24 hours (A-C) or with the same percentage of DMSO (0.01%) to which experimental wells were exposed (D-488nm laser, E-633nm laser and F-bright field). To examine the role of caspase-1 in staurosporine-induced apoptosis and probe activation, cells were coincubated in caspase-1 inhibitor (10 µM) and staurosporine (G-I). Staurosporine induces apoptosis, indicated by the positive annexin staining viewed with the 488-nm laser (A), which colocalized with activated probe viewed with the 633-nm laser (B). Coincubation of the caspase-1 inhibitor with staurosporine did not completely block apoptosis, indicated by the relatively higher number of apoptotic cells stained with annexin (G), as those that activated the probe (H). Magnification, x 40; scale bar, 50 µM.

cleaved-caspase 3; 

PubMed: 19840952     


Representative images (×1000 magnification) showing vehicle treated (C) and staurosporine treated (D) cells stained with anti-cleaved caspase 3 antibody and DAPI.

FAK 4.47; 

PubMed: 15121855     


BT-20 or BT-474 cell culture were plated on six-well plates and were treated with staurosporine (200 nM) after 24 h. After 6 h of treatment, cells were immunostained with anti-FAK 4.47 antibody (white arrowheads mark some focal adhesions).

25215174 22684244 19880522 15140398 19840952 15121855
In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID